PODIUM SESSION II: CANCER OUTCOMES RESEARCH STUDIES

CN1
MLING THE IMPACT OF TECHNOLOGY DIFFUSION IN BREAST CANCER TREATMENT ON THE COST-EFFECTIVENESS OF MAMMOGRAPHY SCREENING
Shih YCT1, Venier J1, Munsell M1, Cantor SB1, Elting LS2, Ravdin P3, Berry DA1
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Adjuvant Online, San Antonio, TX, USA, 3UCLA, Los Angeles, CA, USA
OBJECTIVES: The association between treatment advances and dissemination and the cost-effectiveness of screening is largely unknown. This study addressed the above association among breast cancer patients. METHODS: Using a Bayesian micro-simulation model, we followed a hypothetical cohort of 1 million women born in 1960 throughout their lifetimes. We compared no screening strategy to eight mammography screening strategies that consisted of a combination of different initiation age (40 vs. 50), cessation age (74 vs. 79), and frequency (annual vs. biennial) of screening. Upon identifying the most cost-effective strategy, we then applied probabilistic sensitivity analyses (PSA) to explore the impact of different patterns of treatment dissemination on the cost-effectiveness of screening. RESULTS: At the societal willingness-to-pay (£100,000 per life year (LY)) gained and with the dissemination pattern prior to the availability of trastuzumab, the most cost-effective screening strategy was biennial screening for women aged 50–74. The probability that this strategy was more cost-effective than the no screening strategy was 0.43, followed by biennial screening 50–79 (prob. = 0.041), biennial screening 40–79 (prob. = 0.08), and biennial screening 40–74 (prob. = 0.084). At a WTP of £100,000/LY, the probabilities increased to 0.089, 0.87, and 0.82, respectively. Results from the PSA indicated that when adding trastuzumab to the base case dissemination pattern, the probability that the biennial screening 50–74 strategy was more cost-effective than the no screening strategy at a WTP of £100,000/LY decreased from 0.89 to 0.83, and the probability of the no screening strategy increasing to 0.061 if the optimal dissemination pattern (i.e., all patients with HER2 overexpression received trastuzumab) was achieved. CONCLUSIONS: The finding that improvements in treatment dissemination may paradoxically lead to a reduction in the cost-effectiveness of screening suggests that identifying and designing cost-effective strategies to allocate health care resources across the continuum of cancer care is likely to yield higher gains.

USE OF LATENT VARIABLE AND SURVIVAL MODELING TO ESTIMATE THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND PROGRESSION-FREE SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA
Hassan Hamed1,2, Stockl KM3, Shin J4, Harada AS5, Lew HC6, Solow BK7, Curtis BS8
1Walden University, Minneapolis, MN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: The purpose of this study was to conduct joint modeling of latent growth curve models (LGCMs) for patient-reported outcomes (PROs) and survival models for progression-free survival (PFS) to estimate their association in previously-treated patients with advanced malignant pleural mesothelioma (MPM). METHODS: Post-hoc analyses were conducted on PRO and PFS data collected from 243 patients in a phase III randomized controlled trial of best supportive care (BSC) versus pemetrexed plus-BSC. PFS was a secondary end point in the original study; PRO data were collected using the Lung Cancer Symptom Scale (LCSS). LGCMs were constructed for the nine LCSS items including a treatment covariate; PFS was then regressed onto the intercept of pain (<.001), and the slope of global quality of life (<.001). First, the EQ-5D, a widely used measure of health-related quality of life (HRQOL), and the slope of global quality of life (p < .001), and the slope of global quality of life (p < .001) from the LGCMs; no growth factors were associated with fatigue or treatment. The joint hemoptysis model did not converge therefore the association between PFS and hemoptysis cannot be assessed. CONCLUSIONS: Joint modeling with PSA accounted for censoring of LCVM observations and increased our ability to estimate latent growth factors. This provided further insight into the meaningfulness and significance of PFS by allowing more accurate estimate of patient symptom levels that were associated with the progression-free disease interval. Application of these methods can help MPM patients, caregivers, providers, and payers to make more informed health care decisions. Further research in other cancers is needed to determine if these findings are generalizable.

DIRECT MEDICAL COSTS OF TREATMENT OF METASTATIC BREAST CANCER AFTER ANTIRHEUMYCL AND TAXANES FAILURE FROM THE MEXICAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Javier-Garcia A1, Vargas-Velencs 2, Martinez-Fonsca J3, Del-Coyac R4, Bargallo-Rocha P1, Herlough JF1, Gonzalez-Roy X5
1Bristol Myers Squibb, D.F., Mexico, 2Econopharma Consulting S. A. de C. V., Mexico City, Mexico, 3Instituto Nacional de Cancerología, Mexico, DF, Mexico
OBJECTIVES: To define resources and procedures to set the direct medical costs of treatment of metastatic breast cancer (MBC) after antirheumycl and taxanes failure from the Mexican public health system perspective. METHODS: The unitary costs of chemotherapy, surgery, radiotherapy and hormonal therapy were obtained through quantification the consumption of health care resource reported in 873 clinical files of patients with advanced breast cancer patients after failure to antirachyycls and taxanes with at least two years follow-up treated at three tertiary public hospitals in Mexico: Hospital de Oncología del Centro Médico Siglo XXI del Instituto Mexicano del seguro Social (SigloXXI) (47%), Instituto Nacional de Cancerología (INCAN) (42%) and Centro Universitario de Cancer (CUC) (11%). All costs (drugs, services and procedures) were obtained from institutional sources and expressed in 2009 US$. RESULTS: The mean unitary cost of surgery at the SigloXXI (n = 26) is US$277.31 ($168.31-$266.93), at the CUC (n = 16) US$306.14 ($224.68-$381.70), and at the INCAN (n = 20) US$288.36 ($190-390). CONCLUSIONS: CONCLUSIONS: The treatment costs vary widely within every center, as result of the clinical practice variability, but seem consistent between centers included in this analysis with no significant statistical differences.

PODIUM SESSION II: HEALTH CARE MANAGEMENT STUDIES

CN2
CLINICAL, ECONOMIC, AND HUMANISTIC BENEFITS OF A RHEUMATOID ARTHRITIS DISEASE THERAPY MANAGEMENT PROGRAM
Soccol KP1, Shih J1, Harada AS2, Lew HC2, Solow BK3, Curtis BS4
1Prescription Solutions, Irvine, CA, USA, 2USF, 3UCSF, 4UCLA
OBJECTIVES: To evaluate clinical, economic, and humanistic outcomes of a rheumatoid arthritis (RA) disease therapy management (DTM) program designed to improve self-management of injectable RA medication therapy. METHODS: Patient-reported outcomes among patients (N = 171) completing a 7-month RA DTM program were compared from Month 0 to Month 6 using the Short Form (SF)-12, Work Productivity Activity Impairment (WPAI), and Health Assessment Questionnaire (HAQ)-Disability (D) (WPAI tools. Propensity scoring was used to match these two groups with non-DTM cohorts who filled injectable RA medications at specialty or retail pharmacies (N = 248 in each cohort). Adherence to injectable RA medications was measured by calculating the medication possession ratio (MPR) over an 8-month post-period. Among the subgroup of patients with medical claims data in the DTM (N = 46), specialty (N = 55) and retail (N = 32) cohorts, changes in pharmacy, medical, and total health care costs per patient per month (PPPM) were compared from the pre- and post-periods. RESULTS: SF-12 physical component scores significantly increased by 1.1 points (p = 0.048), SF-12 mental component scores were not significantly changed. WPAI work productivity decreased by 10.8% (p = 0.045), and HAQ-DI scores significantly improved by 0.08 points (p = 0.003). DTM patients had significantly higher medication adherence compared with specialty or retail pharmacy patients (MPR 0.91, 0.83, and 0.61, respectively; p < 0.0001). Median pharmacy costs increased by $25.78, $20.39, and $7.27 PPPM, respectively (p < 0.001 for DTM vs. retail). Total health care costs per patient increased for DTM and retail cohorts ($22.48, and $27.22 PPPM, respectively). CONCLUSIONS: Patients completing the RA DTM program experienced increased medication adherence and improvements in SF-12 physical component and HAQ-DI scores, but did not have improved SF-12 scores.